Analyst Price Target is $25.00
▲ +575.68% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Relmada Therapeutics in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 575.68% upside from the last price of $3.70.
Current Consensus is
N/A
The current consensus among 0 investment analysts is to n/a stock in Relmada Therapeutics. This N/A consensus rating has held steady for over two years.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Read More